AMJEVITA

targets

all catalysts(13)

News(9)

• BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffs
  BMO Capital Markets is more impressed by Merck’s plans to replace lost Keytruda revenue than on Bristol Myers Squibb’s efforts to fill the expected void that will come from loss of exclusivity for…
  biospace · 1d ago
• Merck’s antibody impresses with ‘highly competitive’ data in chronic skin disease
  Merck has revealed detailed data for tulisokibart from a mid-stage trial in hidradenitis suppurativa that analysts say could help carve out a place in a crowded market that already includes AbbVie’…
  biospace · 2d ago
• 6 immunology targets to sustain a mammoth I&I market
  Johnson & Johnson, Pfizer, Argenx and more are unlocking new immunology targets and looking to improve on existing ones in an attempt to catch some of the magic brought about by AbbVie’s Humira and…
  biospace · 6d ago
• Drugmakers cherry pick launch regions as MFN creates 'policy environment like an earthquake'
  With multiple drug pricing initiatives like Most Favored Nation now in force, drugmakers have to reinvent their commercial strategies to stay ahead of the fast-moving policy environment, according…
  biospace · 23d ago
• MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial
  MoonLake Immunotherapeutics announced positive phase 3 data for patients with psoriatic arthritis treated with its lead nanobody candidate, sonelokimab.
  fiercebiotech · 1mo ago
• AbbVie shares pressured as Q2 I&I beat falls below investor expectations
  AbbVie investors’ sky-high expectations led to a 4% share decline on Friday as the company reported more modest consensus beats than expected.
  biospace · 2mo ago
• cAMPfield lands $180M to build gut disease drug
  The biotech is advancing an anti-inflammatory drug that originated with vTv for inflammatory bowel diseases, leaning on a better side effect profile.
  biopharma_dive · 3mo ago
• Biogen adds more immune drugs in $1B buyout of secretive startup RayThera
  The companies didn’t specify the drugs Biogen is acquiring in the deal, though patents RayThera secured provide important clues.
  biopharma_dive · 3mo ago
• Opinion: The podcast telling the stories behind Ambien, Ozempic, EpiPens, and other game-changing drugs
  “We're basically not using our body as directed,” says "Drug Story" host Thomas Goetz.
  stat · 5mo ago